{"description":"Documents matching 'cannabis OR marijuana' and from Drug Enforcement Administration","count":92,"total_pages":5,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bagencies%5D%5B%5D=drug-enforcement-administration&conditions%5Bterm%5D=cannabis+OR+marijuana&format=json&page=2","results":[{"title":"Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements","type":"Rule","abstract":"With the issuance of this final rule, which constitutes a final order, the Acting Attorney General of the U.S. Department of Justice places drug products containing marijuana that have been approved by the Food and Drug Administration (FDA) in schedule III of the Controlled Substances Act (\"CSA\"). This action is required to satisfy the responsibility of the Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961. In general, this final rule applies to marijuana as defined in the CSA, marijuana extracts, and delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant (other than the mature stalks and seeds) that falls outside the definition of hemp, to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes (\"state medical marijuana license\"). Also consistent therewith, this final rule adds such drugs to the list of substances that may only be imported or exported pursuant to a permit. This final rule also establishes an expedited registration process under 21 CFR part 1301 for entities holding state medical marijuana licenses, enabling such entities to engage in the manufacture, distribution, and/or dispensing of marijuana for medical purposes under federal law consistent with the requirements of the Single Convention.","document_number":"2026-08176","html_url":"https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-28/pdf/2026-08176.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08176.pdf?1777293907","publication_date":"2026-04-28","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"medical <span class=\"match\">marijuana</span> licenses from the requirement to monopolize the wholesale trade in <span class=\"match\">marijuana</span>. \n \n This final rule rescheduling <span class=\"match\">marijuana</span> contained in FDA-approved products or subject to a state medical <span class=\"match\">marijuana</span> license applies to <span class=\"match\">marijuana</span> as listed in 21 CFR 1308.11(d)(23), as well as <span class=\"match\">marijuana</span> extracts as defined in 21 CFR 1308.11(d)(58) because they meet the statutory definition of <span class=\"match\">marijuana</span> and, prior to 2017, were included in 21 CFR 1308.11(d)(23).\n 38 \n \n In addition, this final \n \n rule applies to Δ9-THC derived from the <span class=\"match\">marijuana</span> plant"},{"title":"Schedules of Controlled Substances: Rescheduling of Marijuana","type":"Proposed Rule","abstract":"The Department of Justice (\"DOJ\") proposes to transfer marijuana from schedule I of the Controlled Substances Act (\"CSA\") to schedule III of the CSA, consistent with the view of the Department of Health and Human Services (\"HHS\") that marijuana has a currently accepted medical use as well as HHS's views about marijuana's abuse potential and level of physical or psychological dependence. The CSA requires that such actions be made through formal rulemaking on the record after opportunity for a hearing. If the transfer to schedule III is finalized, the regulatory controls applicable to schedule III controlled substances would apply, as appropriate, along with existing marijuana-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If marijuana is transferred into schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA's definition of \"marijuana\" would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act (\"FDCA\"). DOJ is soliciting comments on this proposal.","document_number":"2024-11137","html_url":"https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-21/pdf/2024-11137.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-11137.pdf?1715958912","publication_date":"2024-05-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"constituency among <span class=\"match\">marijuana</span> samples and that the interpretation of clinical data related to <span class=\"match\">marijuana</span> is complicated. A primary issue is the lack of consistent concentrations of Δ9-THC and other substances in <span class=\"match\">marijuana</span>, which complicates the interpretation of the effects of different <span class=\"match\">marijuana</span> constituents. Additionally, the non-cannabinoid components in <span class=\"match\">marijuana</span> may potentially modify the overall pharmacological and toxicological properties of various <span class=\"match\">marijuana</span> strains and products. DEA anticipates that additional data on other <span class=\"match\">marijuana</span> constituents"},{"title":"Decision and Order: Medpharm Research, LLC","type":"Notice","abstract":null,"document_number":"2026-20553","html_url":"https://www.federalregister.gov/documents/2026/10/07/2026-20553/decision-and-order-medpharm-research-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-07/pdf/2026-20553.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20553.pdf?1791290716","publication_date":"2026-10-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"continues to operate, as a <span class=\"match\">marijuana</span> cultivation facility, growing both medical and recreational <span class=\"match\">marijuana</span>, which is sold to third-party <span class=\"match\">marijuana</span> dispensaries operating within Colorado's <span class=\"match\">marijuana</span> market. RFAAX 1, at 4.\n \n IV. Discussion \n \n Here, Applicant's parent company, MedPharm Holdings, and its sister company, MX, have been manufacturing <span class=\"match\">marijuana</span> without DEA registration for at least the past 10 years. RFAAX 1, at 4. Further, Applicant's parent company and sister company have been engaged in the manufacture of <span class=\"match\">marijuana</span> for sale in the recreational"},{"title":"JT Medical, LLC; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-19842","html_url":"https://www.federalregister.gov/documents/2026/09/29/2026-19842/jt-medical-llc-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19842.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19842.pdf?1790599512","publication_date":"2026-09-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Approved Products Containing <span class=\"match\">Marijuana</span> From Schedule I to Schedule III; Corresponding Change to Permit Requirements, \n 91 FR 22714, 22721 (2026) (adding paragraph (k) to 21 CFR 1301.13 “establish[ing] an expedited review process for entities holding state medical <span class=\"match\">marijuana</span> licenses who seek registration as a <span class=\"match\">marijuana</span> manufacturer”); \n see also id. \n at 22722 (adding paragraphs (g)(2)-(4) to 21 CFR 1308.13 placing into schedule III marihuana, marihuana extract, and delta-9-tetrahydrocannabinols “subject to a state medical <span class=\"match\">marijuana</span> license”).\n \n \n Order"},{"title":"MCRGC, LLC; Decision and Order","type":"Notice","abstract":null,"document_number":"2025-19613","html_url":"https://www.federalregister.gov/documents/2025/10/21/2025-19613/mcrgc-llc-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-10-21/pdf/2025-19613.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-19613.pdf?1760964308","publication_date":"2025-10-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"(citing 21 U.S.C. 823(a)).\n \n \n More specifically, the OSC alleged that Applicant did not have: (1) a physical location for its establishment to grow <span class=\"match\">marijuana</span> that DEA can inspect; (2) state licensure in any state for growing <span class=\"match\">marijuana</span>; (3) a DEA Schedule I researcher certificate of registration; and (4) a bona fide supply agreement with a registered DEA Schedule I researcher with a DEA approved <span class=\"match\">marijuana</span> research protocol. \n Id. \n at 1 (citing 21 U.S.C. 822(f), 21 U.S.C. 823(a), and 21 CFR 1318.05(b)). On June 28, 2024, the Government submitted an"},{"title":"Muhamad Aly Rifai, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21258","html_url":"https://www.federalregister.gov/documents/2026/10/19/2026-21258/muhamad-aly-rifai-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-19/pdf/2026-21258.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21258.pdf?1792154712","publication_date":"2026-10-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"that she had used <span class=\"match\">cannabis</span> to alleviate anxiety or lessen alcohol use, or that she possessed a medical <span class=\"match\">marijuana</span> card. RFAAX 28, at 6. The transcripts of UC's interaction with Respondent and his staff confirm UC's statement that she never told Respondent that she had used <span class=\"match\">cannabis</span> or possessed a <span class=\"match\">marijuana</span> card. \n See \n RFAAX 39, at 1-26; \n see also \n RFAAX 28, at 1-7. However, Respondent's records include an evaluation stating that “[UC] admits to periodic <span class=\"match\">cannabis</span> use to help anxiety, less alcohol use. Reports Medical <span class=\"match\">Marijuana</span> Card. Could not find"},{"title":"Schedules of Controlled Substances: Placement of Diphenidine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places the substance diphenidine (1-(1,2- diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.","document_number":"2026-19231","html_url":"https://www.federalregister.gov/documents/2026/09/21/2026-19231/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19231.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19231.pdf?1789735510","publication_date":"2026-09-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I","type":"Rule","abstract":"With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing 2-(4- methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (other names: N-pyrrolidino metonitazene or metonitazepyne) and 5- nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (other names: N-pyrrolidino protonitazene or protonitazepyne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I under the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1961 Single Convention on Narcotic Drugs. This action imposes permanent regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with or possess), or handle N-pyrrolidino metonitazene and N-pyrrolidino protonitazene.","document_number":"2026-00362","html_url":"https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-12/pdf/2026-00362.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00362.pdf?1767966316","publication_date":"2026-01-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the test was not satisfied. In a recent published letter in a different"},{"title":"Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I","type":"Rule","abstract":"With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing N-ethyl-2- (2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name: N-desethyl isotonitazene) and 2-(4-ethoxybenzyl)-5-nitro- 1-(2-(piperidin-1-yl)ethyl)-1H-benzimidazole (other names: N- piperidinyl etonitazene; etonitazepipne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I under the Controlled Substances Act. This scheduling action discharges the United States' obligations under the Single Convention on Narcotic Drugs (1961). This action imposes permanent regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with or possess), or handle N-desethyl isotonitazene and N-piperidinyl etonitazene.","document_number":"2025-23717","html_url":"https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23717.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-23717.pdf?1766411118","publication_date":"2025-12-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; iii. there must be adequate and well-controlled studies proving efficacy; iv. the drug must be accepted by qualified experts; and v. the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the test was not satisfied. In a recent published letter in a different"},{"title":"Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places substance 3-methoxyphencyclidine (1-(1-(3- methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 3-MeO-PCP.","document_number":"2026-05618","html_url":"https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05618.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05618.pdf?1774010717","publication_date":"2026-03-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n All. for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test was"},{"title":"Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-fluoroamphetamine (4-FA; 1-(4- fluorophenyl)propan-2-amine; para-fluoroamphetamine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4-fluoroamphetamine.","document_number":"2026-00633","html_url":"https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00633.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00633.pdf?1768398308","publication_date":"2026-01-15","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3- b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.","document_number":"2026-09566","html_url":"https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09566.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09566.pdf?1778589924","publication_date":"2026-05-13","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 2-[[1-(4-fluorobutyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA), N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1- yl)-1H-indazole-3-carboxamide (other name: ADB-4en-PINACA), ethyl 2- [[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201), and methyl 2-(1-(4- fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate (other name: MMB-FUBICA), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4F-MDMB-BUTICA, ADB- 4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA.","document_number":"2026-08517","html_url":"https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08517.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08517.pdf?1777553120","publication_date":"2026-05-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-chloromethcathinone (4-CMC, 1-(4-chlorophenyl)- 2-(methylamino)propan-1-one), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4- chloromethcathinone.","document_number":"2025-20004","html_url":"https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-17/pdf/2025-20004.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20004.pdf?1763127920","publication_date":"2025-11-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; iii. there must be adequate and well-controlled studies proving efficacy; iv. the drug must be accepted by qualified experts; and v. the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter. In a recent published"},{"title":"Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I","type":"Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2- [(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.","document_number":"2026-12654","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12654/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12654.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12654.pdf?1782218712","publication_date":"2026-06-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the test was not satisfied. In a recent published letter in a different"},{"title":"Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H- indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.","document_number":"2026-08104","html_url":"https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-24/pdf/2026-08104.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08104.pdf?1776948327","publication_date":"2026-04-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing methyl 2- [[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA), N-(1-amino-3,3-dimethyl-1- oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide (other name: ADB-4en-PINACA), ethyl 2-[[1-(5-fluoropentyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F- EDMB-2201), and methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)- 3-methyl butanoate (other name: MMB-FUBICA), including their salts, isomers (including optical, positional, and geometric isomers), and salts of isomers, in schedule I of the Controlled Substances Act. 4F- MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA were temporarily scheduled in an order dated December 12, 2023. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA.","document_number":"2025-22963","html_url":"https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-16/pdf/2025-22963.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-22963.pdf?1765806325","publication_date":"2025-12-16","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. See \n <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I","type":"Proposed Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one (commonly known as 2-fluorodeschloroketamine or 2-FDCK), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 2-fluorodeschloroketamine.","document_number":"2026-00954","html_url":"https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-20/pdf/2026-00954.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00954.pdf?1768571116","publication_date":"2026-01-20","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the test was not satisfied. In a recent published letter in a different"},{"title":"Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action also enables the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action makes permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.","document_number":"2026-04112","html_url":"https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-02/pdf/2026-04112.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-04112.pdf?1772199926","publication_date":"2026-03-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted medical use in this matter and concluded the test"},{"title":"Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I","type":"Proposed Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notification of intent to publish a temporary order to schedule 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle bromazolam.","document_number":"2025-22763","html_url":"https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-15/pdf/2025-22763.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-22763.pdf?1765547117","publication_date":"2025-12-15","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for <span class=\"match\">Cannabis</span> Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the test was not satisfied. In a recent published letter in a different"}]}